MedTrace Logo

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

NCT05653180 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-04-03

No results posted yet for this study

Summary

This research study is designed to establish whether the combination of IBI310 \& Sintilimab has efficacy in patients with advanced BTC

Conditions

  • Advanced Biliary Tract Cancer

Interventions

DRUG

IBI310

2mg/kg IV,3 weeks later, 1mg/kg IV Q6W

DRUG

sintilimab

200mg IV Q3W

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-10
Primary Completion
2023-12-31
Completion
2024-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05653180 on ClinicalTrials.gov